Results 161 to 170 of about 4,502 (202)

Aprepitant

Drugs, 2009
Aprepitant (Emend) is a neurokinin-1 (NK(1)) receptor antagonist that is able to alleviate the emetic effects of substance P. When combined with a standard regimen of a corticosteroid (dexamethasone) and a serotonin 5-HT(3) receptor antagonist (ondansetron), oral aprepitant (125 mg on day 1 then 80 mg once daily on days 2 and 3) was effective in the ...
Monique P, Curran, Dean M, Robinson
openaire   +2 more sources

Aprepitant: Review on Solubility Enhancement

Recent Advances in Drug Delivery and Formulation
Introduction: Substance P and its neurokinin (NK-1) receptors are upregulated in different pathophysiological conditions. Overexpression of the NK-1 receptor in cancer conditions has provided a promising pathway for cancer treatment. Clinically, Aprepitant (APT) is used as the only NK-1 antagonist in chemotherapy-induced nausea and vomiting (CINV ...
Lata, Kothapalli, Navdeep, Singh, Abhay, Upare, Anil Kumar, Rathour, Nisha, Nikam, Asha, Thomas, Sanjeevani S, Deshkar   +6 more
openaire   +2 more sources

Aprepitant/ifosfamide

Reactions Weekly, 2023
openaire   +2 more sources

Aprepitant

2022
openaire   +1 more source

Aprepitant

Drugs, 2012
Monique P Curran, Dean M Robinson, Curran Monique P   +2 more
exaly   +2 more sources

Aprepitant Capsules

2021
openaire   +2 more sources

Aprepitant as anticancer drug

2008
The present invention relates to the use of a heterocyclic compound according to generalstructural formula (I) for the treatment of cancer. In a preferred aspect the compound according 5to formula (I) is aprepitant.BACKGROUND OF THE INVENTIONCancer is a disorder in which a population of cells has become, in varying degrees, unresponsive 10to the ...
MICHAEL KHUN, PEER BORK, COSTI, Maria Paola, LUCIANI, Rosaria   +3 more
openaire   +1 more source

Aprepitant

Reactions Weekly
openaire   +2 more sources

Aprepitant, Cápsulas

2022
openaire   +2 more sources

Aprepitant/ondansetron

Reactions Weekly, 2021
openaire   +1 more source